News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs
Korean authorities continue to place pressure on the CDMO, after prosecutors raided the office of the national stock exchange regarding behaviour preceding the public listing of Samsung BioLogics.
The EMA completes another step of its transition from London to Amsterdam, as it is now “settled” in the temporary Spark building.
Vertex’s Symdeko approved in Australia, after FDA approval in 2018, as the company works to develop triple combination gene therapies for CF.